Evolus (EOLS) Stock Forecast & Price Target

Evolus is a Buy-rated medical aesthetics company with a $13 price target, based on comparative pharmaceutical multiples and in line with the Consumer MedTech peer group. Although there are risks to this rating and target, such as potential supply chain challenges and regulatory delays, we remain positive on Evolus's future performance due to its innovative products, increasing market share, and expected double-digit revenue growth over the next three years. Additionally, despite challenges in the aesthetics market, Evolus has shown strong resilience and has achieved a ~14% market share with its Jeuveau product.

Evolus is facing several headwinds in the aesthetic market, including a negative consumer spending environment, competition from larger companies in the market, pricing pressure, and supply chain challenges. Additionally, their launch of Evolysse in the US and Estyme internationally may not have a significant impact on revenue and market share due to weak market conditions. Furthermore, their margin expansion and long-term financial outlook have been lowered, indicating potential challenges in meeting their goals in the current market climate. These factors, along with past market slowdowns, contribute to our negative outlook.